A PK and PD Study of Two Formulations of Omega-3 One Gram Capsules

Summary

Comparative bioavailability and pharmacodynamics effects of MAT9001 versus an active omega-3 medication comparator.

Timeline

Start

2014-11

Primary completion

2015-05

Completion

2016-08

Outcome

Met primary endpoint

release “MAT9001 met all primary and secondary endpoints in a head-to-head comparative pharmacokinetic and pharmacodynamic study versus Vascepa ®” matinasbiopharma.com ↗

release “In Matinas BioPharma’s head-to-head comparative pharmacokinetic and pharmacodynamic study versus Amarin’s Vascepa ® (icosapent ethyl), MAT9001 met all of its primary and secondary endpoints” matinasbiopharma.com ↗

Publications

• Maki KC, Bobotas G, Dicklin MR, Huebner M, Keane WF. Effects of MAT9001 containing eicosapentaenoic acid and docosapentaenoic acid, compared to eicosapentaenoic acid ethyl esters, on triglycerides, lipoprotein cholesterol, and related variables. J Clin Lipidol. 2017 Jan-Feb;11(1):102-109. doi: 10.1016/j.jacl.2016.10.010. Epub 2016 Oct 18.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	EPA ethyl esters	Unknown	4 g	—
Subject	OMEGA-3-PENTAENOIC ACIDS	Small molecule	4 g	—

Indications